Will 'Vant' Deal Really Fulfill Dainippon's Needs?
Sumitomo Dainippon's planned $3bn deal with Roivant goes some way to fulfilling the Japanese firm's strategic needs, but investors appear cool and questions remain.
You may also be interested in...
Kynmobi is an important approval for parent company Sumitomo Dainippon ahead of the loss of exclusivity for Latuda. Sunovion hopes to launch after COVID-19 social distancing requirements ease.
Japanese firm backs off potential acquisition of Australian cell therapy venture after the two sides fail to agree on deal terms.
Dermatology-focused regenerative medicine firm Fibrocell has been reviewing strategic opportunities for more than a year; April’s FCX-007 license deal with Castle Creek results in buyout.